A subsequent study by Su et al. [138] found that amentoflavone combined with sorafenib inhibited NF-κB nuclear translocation, NF-κB phosphorylation, and the metastatic ability of U-2 OS cells, leading to apoptosis and inhibition of Erk/NF-κB signaling, sensitizing osteosarcoma cells to sorafenib treatment. Here, NFKB1 is linked to osteosarcoma.